This segment focuses on developing and commercializing therapies for endocrine disorders, with a primary emphasis on diabetes and severe hypoglycemia. Key products include Gvoke, a ready-to-use liquid glucagon formulation designed for ease of use in emergency situations. Research and development efforts are directed towards improving glucagon delivery methods and expanding the applications of Gvoke to address broader patient needs. The segment leverages Xeris's XeriSol and XeriJect technology platforms to enhance drug stability and administration. The goal is to provide patients with convenient and effective solutions for managing their endocrine conditions, improving their quality of life and reducing the burden of disease. Future opportunities include exploring new indications for glucagon and developing innovative combination therapies.

The neurology segment is dedicated to developing treatments for neurological disorders, particularly rare conditions like primary periodic paralysis. The main product in this area is Keveyis, a therapy specifically designed to manage and alleviate the symptoms of this debilitating condition. Research efforts are focused on understanding the underlying mechanisms of neurological diseases and identifying novel therapeutic targets. Xeris utilizes its proprietary formulation technologies to create drugs that are more effective and easier to administer. The segment aims to improve the lives of patients with neurological disorders by providing targeted therapies that address their specific needs. Future growth potential lies in expanding the applications of existing products and developing new treatments for other neurological conditions with high unmet medical needs.

This segment is focused on addressing unmet needs in gastroenterological disorders. While specific marketed products within this segment are not explicitly detailed in the provided context, Xeris's overall strategy of leveraging its XeriSol and XeriJect technology platforms suggests a commitment to developing innovative drug delivery solutions for gastrointestinal conditions. Research and development activities likely involve exploring new formulations and delivery methods to improve the efficacy and patient experience of existing gastroenterology treatments. The segment aims to provide targeted therapies that address specific gastrointestinal disorders, improving patient outcomes and quality of life. Future opportunities may include developing novel treatments for inflammatory bowel disease, irritable bowel syndrome, and other common gastrointestinal conditions.